Legend Biotech Corporation
LEGN
$34.70
$0.421.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 117.92% | 120.66% | 174.02% | 229.60% | 165.07% |
| Total Other Revenue | 3,395.53% | 1,740.61% | 1,458.18% | 903.49% | -77.43% |
| Total Revenue | 119.97% | 122.96% | 176.93% | 231.84% | 163.30% |
| Cost of Revenue | 23.12% | 23.55% | 23.53% | 27.65% | 31.34% |
| Gross Profit | 91.34% | 66.09% | 55.89% | 35.00% | 17.51% |
| SG&A Expenses | 41.48% | 37.94% | 26.76% | 20.35% | 15.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.19% | 27.58% | 24.42% | 25.53% | 26.53% |
| Operating Income | 31.00% | 21.90% | 25.61% | 15.70% | 5.22% |
| Income Before Tax | 69.60% | 32.13% | 45.97% | 10.97% | -14.39% |
| Income Tax Expenses | 1,113.57% | 844.17% | -383.68% | -436.78% | -503.46% |
| Earnings from Continuing Operations | 65.84% | 31.65% | 46.43% | 11.44% | -13.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.84% | 31.65% | 46.43% | 11.44% | -13.87% |
| EBIT | 31.00% | 21.90% | 25.61% | 15.70% | 5.22% |
| EBITDA | 31.80% | 22.48% | 26.22% | 16.07% | 5.46% |
| EPS Basic | 67.21% | 35.97% | 50.45% | 20.47% | -3.20% |
| Normalized Basic EPS | 71.55% | 36.46% | 50.07% | 20.14% | -3.74% |
| EPS Diluted | 67.27% | 36.04% | 50.49% | 20.37% | -3.43% |
| Normalized Diluted EPS | 70.81% | 36.46% | 50.07% | 20.14% | -3.74% |
| Average Basic Shares Outstanding | 3.88% | 6.21% | 9.08% | 11.38% | 10.66% |
| Average Diluted Shares Outstanding | 6.45% | 6.21% | 9.08% | 11.38% | 10.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |